Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr Moustafa on the Evolution of Treatment Options for Patients With MCL

October 20th 2023

Muhamad Alhaj Moustafa, MD, MS, discusses the evolution of treatment options for patients with mantle cell lymphoma.

Dr Ahmed on a Study of Real-World Outcomes With Brexu-Cel in Relapsed/Refractory MCL

October 19th 2023

Nausheen Ahmed, MD, discusses the rationale and design of a subgroup analysis of real-world outcomes with brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma.

Dr Moustafa on the Influence of the SHINE Trial in MCL

October 17th 2023

Muhamad Alhaj Moustafa, MD, MS, discusses the phase 3 SHINE trial, which evaluated ibrutinib given with bendamustine and rituximab in patients with mantle cell lymphoma.

Dr. Moustafa on Clinical Implications of the BRUIN Trial of Pirtobrutinib in MCL

October 6th 2023

Muhamad Alhaj Moustafa, MD, MS, has improved the treatment of patients with mantle cell lymphoma, and the role that this agent has in the current treatment landscape.

Dr Kahl on Ongoing and Planned Investigations Within the Landscape of MCL

October 5th 2023

Brad S. Kahl, MD, discusses ongoing and planned investigations within the landscape of mantle cell lymphoma.

Dr Phillips on the Evolving Treatment Landscape in MCL

October 4th 2023

Tycel Phillips, MD, discusses current and emerging therapeutic treatment strategies for patients with mantle cell lymphoma.

Dr Phillips on the Use of Bispecific Antibodies and CAR T-Cell Therapy in MCL and FL

September 20th 2023

Tycel Phillips, MD, MPH, discusses the use of bispecific antibodies and CAR T-cell therapy across hematologic malignancies, including in patients with mantle cell lymphoma and follicular lymphoma.

Dr Phillips on Treatment With Bispecific Antibodies and CAR T-Cell Therapy in MCL

September 19th 2023

Tycel Phillips, MD, MPH, discusses treatment with bispecific antibodies and CAR T-cell therapy in patients with mantle cell lymphoma, and other non-Hodgkin lymphomas.

Ongoing Trials Could Shift BTK Inhibitors to Earlier Settings in MCL

September 14th 2023

Brad S. Kahl, MD, discusses the evolving role of BTK inhibitors in the treatment of patients with mantle cell lymphoma, expands on key ongoing trials investigating these agents in earlier settings and in different combinations, and expands on what the addition of pirtobrutinib to the treatment arsenal has meant for this population.

Dr Mead on Unanswered Questions in the Treatment of MCL

September 8th 2023

Monica D. Mead, MD, discusses the importance of addressing unanswered questions in the treatment of patients with mantle cell lymphoma.

Dr Kahl on the Potential for Frontline BTK Inhibitors in Mantle Cell Lymphoma

September 8th 2023

Brad S. Kahl, MD, discusses the potential for BTK inhibitors to shift the frontline treatment setting in mantle cell lymphoma.

Parsaclisib Displays Efficacy in Relapsed/Refractory MCL

September 7th 2023

Treatment with the PI3Kδ inhibitor parsaclisib led to responses with a manageable safety profile in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 CITADEL-205 trial.

Dr Phillips on the Evaluation of Frontline Treatment With Acalabrutinib Plus BR in MCL

August 31st 2023

Tycel Phillips, MD, MPH, discusses the ongoing phase 3 ECHO trial of acalabrutinib plus bendamustine and rituximab in the front line for patients with mantle cell lymphoma.

Dr Kambhampati on the Rationale For Evaluating Real-World Outcomes With Brexu-Cel in MCL

August 30th 2023

Swetha Kambhampati, MD, discusses the rationale for evaluating outcomes with in a subgroup anlaysis of patients with relapsed/refractory mantle cell lymphoma, and how prior data from the phase 3 ZUMA-2 study supported the inception of this trial.

Dr Kambhampati on the Potential Use of Brexu-Cel in Earlier Treatment Lines in MCL

August 29th 2023

Swetha Kambhampati, MD, discusses how findings from a subgroup analysis of investigating the use of brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma may support the continued exploration of this agent in earlier lines of therapy.

Dr Islam on Novel Explorations of BTK Inhibitors in MCL and CLL

August 28th 2023

Prioty Islam, MD, MSc, discusses the exploration of novel roles for BTK inhibitors in the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia.

Dr Mead on the Use of Zanubrutinib vs Ibrutinib in MCL

August 25th 2023

Monica D. Mead, MD, discusses the efficacy and safety differences between the second-generation BTK inhibitor zanubrutinib and the first-generation BTK inhibitor ibrutinib in patients with mantle cell lymphoma.

Dr Mead on the Decreased Use of Ibrutinib in Pretreated MCL

August 24th 2023

Monica D. Mead, MD, discusses reasons for the declining use of the BTK inhibitor ibrutinib in patients with mantle cell lymphoma.

Dr Mead on the Shifting Role of Ibrutinib in the Treatment of MCL

August 23rd 2023

Monica D. Mead, MD, discusses the impact of key data on the role of ibrutinib in the treatment of mantle cell lymphoma.

Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma

August 21st 2023

Monica D. Mead, MD, discusses the evolving use of the BTK inhibitors in the treatment of patients with MCL, the factors for selecting between ibrutinib, zanubrutinib, and acalabrutinib, and unmet needs for patients with MCL.